1.Clinical observation of the changes of cognitive function in patients with cerebral infarction and metabolic syndrome
Chinese Journal of Primary Medicine and Pharmacy 2010;17(16):2212-2214
Objective This study was designed to explore the changes in cognitive function in patients with cerebral infarction and metabolic syndrome(MS). Methods 222 patients diagnosed with the criteria of cerebral infarction were randomly divided into MS,hypertension,diabetes and simple cerebral infarction group(cerebral infarction for clinical observation group).The cognitive function of patients with cerebral infarction was detected with Wechsler memory scale,WMS,scale of elderly cognitive function,SECF and mini-mental state examination,MMSE respectively.After detection with this scales,the cognitive function of these patients with cerebral infarction were analyzed. Results The coarse points,T points,scale score and memory quotient (MQ) of patients with cerebral infarction were significantly lower than the control group(P<0.05,0.01=;SECF detection of long memory points and animal coarse sub in only simple cerebral infarction group was significantly higher than the MS group(P<0.05=.Long memory and recall a rough segmentation of hypertensive group was significantly higher than the MS group(P<0.05=.Comparison of abnormal rate of each group was also only a simple long memory in cerebral infarction group was significantly lower than MS group(P<0.05=; WMS test results for the purely cerebral infarction coarse scale sub-group was significantly higher than MS group(P<0.05,0.01=. Conclusion Cognitive function in patients with cerebral infarction was damaged;MS patients with cerebral was damaged obviously.
2.To effects of Puerarin Injection associated with Irbesartan on Cardiac Insufficiency at Decompensated Stage of chronic corpulmonale heart failure
Zhongyun SUN ; Chao JIANG ; Fengfang LIU ; Mingtang SHAO ; Qingfu KONG
International Journal of Traditional Chinese Medicine 2008;30(3):163-166
ObjectiveTo explore the curative effects of Puerarin Injection associated with Irbesartan on decompensated chronic cor pulmonale heart failure. MethodsA total of 168 cases conforming to the diagnostic standards were randomized into control group (92 cases) and therapy group (76 cases). In the control group: Based on the results of sputum and X-ray, broad-spectrum antibiotics were firstly selected and used for 3 days after admission. Then sensitive antibiotics were selected according to the results of sputum culture and drug sensitivity test. Medicine for relieving cough and asthma, and apophlegmatisant were used routinely. Patients with heart failure were treated with Digoxin or diuresis. In addition to the above treatments, the therapeutic group were treated with Puerarin Injection 600mg and Irbesartan 75mg once a day. The two groups were both treated for 20 days. Results①The incipient slope, 0.8 slope, 0.5 slope and the minimal surplus were all significantly changed (P<0.01) in therapeutic group after the treatment. There were significant difference in the incipient slope, 0.8 slope, 0.5 slope and the minimal surplus before and after treatment both in the control group and therapeutic group. ②The plasma viscosity and blood viscosity decreased observably (P<0.01) after the treatment in the therapeutic group, and more obviously than that in the control group (P<0.01). ③The arterial oxygen pressure (PaO2) and arterial oxygen saturation (SaO2) in the therapeutic group were enhanced more prominently than that of the control group (P<0.01). ④The mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) decreased obviously in the therapeutic group after the treatment, and more observably than those in the control group (P<0.01). ⑤The cardiac output and cardiac index were improved prominently in the therapeutic group after the treatment, and more obviously than that of the control group (P<0.01). ⑥The heart functional capacity (NYHA) improved significantly after the treatment both in the control group and the therapeutic group (P<0.05). ConclusionsPuerarin Injection and Irbesartan could remarkablely change the erytlu'ocyte deformabifity, improve the hemorheology, lower pulmonary hypertension, and improve the cardiac function and the clinical efficacy in decompensation stage.